Baseline patient characteristics, overall and according to funding source
| Characteristic . | Total (N = 1029) . | Public (N = 339) . | Private (N = 682) . | P value . |
|---|---|---|---|---|
| Age (mean ± SD), y | 63.4 ± 11.4 | 63.0 ± 10.9 | 63.5 ± 11.7 | .516 |
| Sex, female | 524/1029 (50.9%) | 156/339 (46.0%) | 363/682 (53.2%) | .030 |
| Country of origin, n (%) | <.001 | |||
| Argentina | 306/1029 (29.7%) | 17/339 (5.0%) | 289/682 (42.4%) | |
| Brazil | 435/1029 (42.3%) | 268/339 (79.1%) | 167/682 (24.5%) | |
| Colombia | 269/1029 (26.1%) | 53/339 (15.6%) | 212/682 (31.1%) | |
| Mexico and Panama | 19/1029 (1.8%) | 1/339 (0.3%) | 14/682 (2.1%) | |
| Race, White | 414/907 (45.6%) | 163/308 (52.9%) | 251/592 (42.4%) | .003 |
| Comorbidities present | 771/985 (78.3%) | 261/318 (82.1%) | 505/682 (76.5%) | .005 |
| Hemoglobin (mean ± SD), g/dL | 10.3 ± 2.39 | 9.6 ± 2.45 | 10.7 ± 2.26 | <.001 |
| Serum creatinine (mean ± SD), mg/dL | 1.80 ± 1.97 | 2.06 ± 2.17 | 1.69 ± 1.87 | .002 |
| Serum calcium (mean ± SD), mg/dL | 9.9 ± 2.91 | 9.9 ± 1.72 | 9.5 ± 1.73 | .146 |
| CRAB features present | ||||
| Hypercalcemia | 87/683 (12.7%) | 43/239 (18.0%) | 39/439 (8.9%) | <.001 |
| Renal dysfunction | 191/866 (22.1%) | 80/283 (28.3%) | 106/575 (18.4%) | .001 |
| Anemia | 414/916 (45.2%) | 173/295 (58.6%) | 237/615 (38.5%) | <.001 |
| Bone lesions | 671/837 (80.2%) | 209/245 (85.3%) | 458/587 (78.0%) | .016 |
| ISS stage | <.001 | |||
| I | 235/870 (27.0%) | 46/258 (17.8%) | 188/606 (31.0%) | |
| II | 252/870 (29.0%) | 69/258 (26.7%) | 181/606 (29.9%) | |
| III | 383/870 (44.0%) | 143/258 (55.4%) | 237/606 (39.1%) | |
| Eligibility to ASCT | .043 | |||
| No | 280/875 (32.0%) | 106/291 (36.4%) | 171/577 (29.6%) | |
| Yes | 595/875 (68.0%) | 185/291 (63.6%) | 406/577 (70.4%) | |
| Age as reason for ineligibility to ASCT∗ | 174/226 (77.0%) | 64/88 (72.7%) | 109/136 (80.1%) | .745 |
| Cytogenetic test performed | 493/830 (59.4%) | 61/252 (24.2%) | 429/570 (75.3%) | <.001 |
| Characteristic . | Total (N = 1029) . | Public (N = 339) . | Private (N = 682) . | P value . |
|---|---|---|---|---|
| Age (mean ± SD), y | 63.4 ± 11.4 | 63.0 ± 10.9 | 63.5 ± 11.7 | .516 |
| Sex, female | 524/1029 (50.9%) | 156/339 (46.0%) | 363/682 (53.2%) | .030 |
| Country of origin, n (%) | <.001 | |||
| Argentina | 306/1029 (29.7%) | 17/339 (5.0%) | 289/682 (42.4%) | |
| Brazil | 435/1029 (42.3%) | 268/339 (79.1%) | 167/682 (24.5%) | |
| Colombia | 269/1029 (26.1%) | 53/339 (15.6%) | 212/682 (31.1%) | |
| Mexico and Panama | 19/1029 (1.8%) | 1/339 (0.3%) | 14/682 (2.1%) | |
| Race, White | 414/907 (45.6%) | 163/308 (52.9%) | 251/592 (42.4%) | .003 |
| Comorbidities present | 771/985 (78.3%) | 261/318 (82.1%) | 505/682 (76.5%) | .005 |
| Hemoglobin (mean ± SD), g/dL | 10.3 ± 2.39 | 9.6 ± 2.45 | 10.7 ± 2.26 | <.001 |
| Serum creatinine (mean ± SD), mg/dL | 1.80 ± 1.97 | 2.06 ± 2.17 | 1.69 ± 1.87 | .002 |
| Serum calcium (mean ± SD), mg/dL | 9.9 ± 2.91 | 9.9 ± 1.72 | 9.5 ± 1.73 | .146 |
| CRAB features present | ||||
| Hypercalcemia | 87/683 (12.7%) | 43/239 (18.0%) | 39/439 (8.9%) | <.001 |
| Renal dysfunction | 191/866 (22.1%) | 80/283 (28.3%) | 106/575 (18.4%) | .001 |
| Anemia | 414/916 (45.2%) | 173/295 (58.6%) | 237/615 (38.5%) | <.001 |
| Bone lesions | 671/837 (80.2%) | 209/245 (85.3%) | 458/587 (78.0%) | .016 |
| ISS stage | <.001 | |||
| I | 235/870 (27.0%) | 46/258 (17.8%) | 188/606 (31.0%) | |
| II | 252/870 (29.0%) | 69/258 (26.7%) | 181/606 (29.9%) | |
| III | 383/870 (44.0%) | 143/258 (55.4%) | 237/606 (39.1%) | |
| Eligibility to ASCT | .043 | |||
| No | 280/875 (32.0%) | 106/291 (36.4%) | 171/577 (29.6%) | |
| Yes | 595/875 (68.0%) | 185/291 (63.6%) | 406/577 (70.4%) | |
| Age as reason for ineligibility to ASCT∗ | 174/226 (77.0%) | 64/88 (72.7%) | 109/136 (80.1%) | .745 |
| Cytogenetic test performed | 493/830 (59.4%) | 61/252 (24.2%) | 429/570 (75.3%) | <.001 |
All numbers and percentages are based on patients with known information. Not all sums of percentages for categories within a variable add up to 100% because of rounding. Funding source could not be ascertained for 8 patients.
SD, standard deviation.
The same patient could have >1 reason, not shown here.